Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children

Completed · Phase 1

Conditions studied: HIV Infections

In brief

The primary objective of this study is to assess the safety and tolerability of tipranavir (TPV) oral formulation and soft gelatin capsules together with low-dose ritonavir in HIV-infected children and adolescents, to provide information concerning the pharmacokinetic characteristics of tipranavir and ritonavir in this age group, and to determine the relative bioavailability of the TPV liquid formulation and TPV capsule formulation in adolescents switching from liquid to capsule. The secondary objective of this study is the determination of the dose of topranavir and ritonavir (TPV/r) in children and adolescents between 2 and 18 years of age required for an adult equivalent systemic exposure of TPV/r 500 mg / 200 mg.

Key facts

Study ID: NCT00076999
Run by: Boehringer Ingelheim
People needed: 115
Starts: 2003-11-01
Last updated by the study team: 2014-05-12

Who can join

Age: 2 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Males and females between 2 and 18 years of age.
A confirmed diagnosis of HIV-1 infection as defined by two positive assays from two different samples taken at least two weeks apart. The two results may be any combination of the following:
HIV ribonucleic acid (RNA) detected by reverse transcriptase (RT)-polymerase chain reaction(PCR) or HIV proviral deoxyribonucleic acid (DNA) detected by PCR HIV culture p24 antigen detection Licensed HIV enzyme-linked immunosorbent assay (ELISA) with confirmatory Western blot
Viral load > 1500 RNA copies/mL.
Acceptable screening laboratory values indicative of adequate baseline organ function. Laboratory values are considered acceptable if severity is no higher than Grade 1 for all tests defined by the Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading Severity of Pediatric Adverse Experiences (> 3 months of age) with the following exceptions:
Grade 2 gamma-glutamyl transferase Grade 2 cholesterol Grade 2 triglycerides
Signed informed consent prior to study participation from the patient or a legal guardian.
Active assent must be given by the patient if the child and/or adolescent is capable of understanding the provided study information (this applies to children with the intellectual age of 7 years or greater)
In the opinion of the investigator, an ability to take medications and comply with the requirements of the protocol.

You may not qualify if…

Female patients of childbearing potential who:
have a positive serum pregnancy test at screening are breast feeding are planning on becoming pregnant are not willing to use two methods of contraception to include at least one barrier method (e.g. latex condom plus spermicidal jelly/foam)
Active hepatitis B or C disease defined as hepatitis B surface antigen (HBsAg) positivity or hepatitis C (HCV) antibody or RNA positivity with aspartate aminotransferase(AST)/ alanine aminotransferase(ALT) > Grade 2.
Life expectancy < 12 months.
Patients who are unwilling to abstain from ingesting contraindicated medications and substances which may significantly affect plasma levels of the study medications, notably:
Grapefruit juice or Seville oranges Herbal preparations containing St. John's Wort or milk thistle Garlic supplements
Active substance abuse.
Use of investigational medications or vaccines within 28 days before study entry or during the trial. Some expanded access antiretroviral medications may be acceptable, but must be approved by sponsor.
Requirement for any therapy for malignancy or immunomodulatory drug (e.g. interferon, cyclosporine, hydroxyurea, interleukin-2) within 28 days of study entry. Replacement intravenous gamma globulin treatment is acceptable.
Any active opportunistic infection within 28 days before study entry or other clinically significant findings that may compromise the outcome of the study.
Patients with malabsorption, severe chronic diarrhea or vomiting (more than two episodes of moderate or severe intensity, not attributed to medication therapy and lasting more than four days) within 28 days of the study.
Evidence or symptoms of encephalopathy or developmental delay that would reduce compliance.

Where it is running

1182.14.00001 Boehringer Ingelheim Investigational Site — Los Angeles, California, United States
1182.14.00006 Boehringer Ingelheim Investigational Site — Los Angeles, California, United States
1182.14.00010 Boehringer Ingelheim Investigational Site — Hartford, Connecticut, United States
1182.14.00004 Boehringer Ingelheim Investigational Site — Chicago, Illinois, United States
1182.14.00008 Boehringer Ingelheim Investigational Site — North Worcester, Massachusetts, United States
1182.14.00009 Boehringer Ingelheim Investigational Site — Springfield, Massachusetts, United States
1182.14.00002 Boehringer Ingelheim Investigational Site — Cleveland, Ohio, United States
1182.14.00007 Boehringer Ingelheim Investigational Site — Memphis, Tennessee, United States
1182.14.00003 Boehringer Ingelheim Investigational Site — Houston, Texas, United States
1182.14.5401 Fundación Huésped — Capital Federal, Argentina
1182.14.55002 — São Paulo, Brazil
1182.14.55003 — São Paulo, Brazil
1182.14.11002 Boehringer Ingelheim Investigational Site — Toronto, Ontario, Canada
1182.14.11001 Boehringer Ingelheim Investigational Site — Montreal, Quebec, Canada
1182.14.33004 Boehringer Ingelheim Investigational Site — Lyon, France
1182.14.33005 Boehringer Ingelheim Investigational Site — Nantes, France
1182.14.33001 Boehringer Ingelheim Investigational Site — Paris, France
1182.14.33002 Boehringer Ingelheim Investigational Site — Paris, France
1182.14.33003 Boehringer Ingelheim Investigational Site — Paris, France
1182.14.33006 Boehringer Ingelheim Investigational Site — Paris, France
1182.14.49002 Boehringer Ingelheim Investigational Site — Berlin, Germany
1182.14.49001 Boehringer Ingelheim Investigational Site — Frankfurt am Main, Germany
1182.14.49004 Boehringer Ingelheim Investigational Site — München, Germany
1182.14.39001 Boehringer Ingelheim Investigational Site — Padova, Italy
1182.14.39003 Boehringer Ingelheim Investigational Site — Roma, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.